Dr. Atkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-4971
Summary
- I am an internationally recognized leader in translational and clinical oncology research. I began my career at Tufts Medical Center before moving to Beth Israel Deaconess Medical Center and being appointed Professor at Harvard Medical School where I served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, as well as Co-PI of the Harvard Skin Cancer SPORE, leader of the Dana Farber Harvard Cancer Center Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE. I also was a Charter member of the NCI Extramural IL-2/LAK Cell Working Group and led its offshoot, the Cytokine Working Group for 2 decades. In 2012, I moved to Georgetown where I am the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology. I lead the Lombardi Immunotherapy Initiative and institutional Pilot Grants Program. My current research focuses on immunotherapy for melanoma and RCC and biomarkers for response and toxicity. I have published over 450 original research and review articles and 5 books and have lectured extensively on these topics. I am past president of the Society for Immunotherapy of Cancer (SITC) and currently co-Chair of the Melanoma Research Foundation Scientific Advisory Council. I was honored as a Giant in Melanoma Therapy by Onclive in 2021 and received the Lifetime Achievement Award from SITC in 2022.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
- Tufts Medical CenterResidency, Internal Medicine, 1980 - 1984
- Tufts University School of MedicineClass of 1980
Certifications & Licensure
- DC State Medical License 2012 - 2024
- MA State Medical License 1982 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Lifetime Achievement Award Society for Immunotherapy of Cancer, 2022
- Giant in Cancer Care: Melanoma OncLive, 2021
- Humanitarian Award Melanoma Research Foundation, 2018
- Join now to see all
Clinical Trials
- The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma Start of enrollment: 2013 Mar 01
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Start of enrollment: 2015 Sep 08
- Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Apr 24
- Join now to see all
Publications & Presentations
PubMed
- 9288 citationsSafety, activity, and immune correlates of anti-PD-1 antibody in cancer.Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27 - 141 citationsWhich drug, and when, for patients with BRAF-mutant melanoma?Sekwon Jang, Michael B. Atkins
The Lancet. Oncology. 2013-02-01 - 1500 citationsAdjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance
The New England Journal of Medicine. 2017-09-10
Journal Articles
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell CarcinomaMichael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Lectures
- Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.2019 ASCO Annual Meeting - 6/1/2019
- Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq TrialMarch 9th, 2023
- Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People with MelanomaMarch 1st, 2023
- Treatment Sequence Studied for Advanced BRAF-Mutant MelanomaOctober 7th, 2022
- Join now to see all
Grant Support
- Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitorsNIH/NCI2018–2023
- Georgetown University, Lombardi Cancer Center Support GrantNIH/NCI2012–2023
- Using Single Cell Transcriptomics to Understand Tumor and Immune Heterogeneity Driving Resistance and to Rationally Select Immune Therapy in Advanced RCCDOD-CDMRP2018–2021
- Institutional Research GrantACS2013–2020
- Eastern Cooperative Oncology GroupNational Cancer Institute2002–2012
- Df/Hcc Kidney Cancer SporeNational Cancer Institute2009–2011
- Developmental Research ProgramNational Cancer Institute2009–2011
- Career Development ProgramNational Cancer Institute2009–2011
- Df/Hcc Renal Cancer SporeNational Cancer Institute2003–2008
- Biologic Therapy Of Melanoma And Renal Cell CancerNational Cancer Institute2002–2006
- Core--Clinical Data ManagementNational Cancer Institute2002
- Trial Of Concurrent Biochemotherapy W/ Cisplatin, Dacarbazine, Vinplastine, IL2National Center For Research Resources1998–1999
- RH Interleukin 12 Administered Subcutaneously In Patients With CancerNational Center For Research Resources1998–1999
- IL 2 Administered By IV In Patients With Advanced Malignant MelonomaNational Center For Research Resources1998–1999
- Phase II Pilot Trial Of Concurrent Biochemotherapy With Cisplatin, DacarbazineNational Center For Research Resources1997
- Phase I Trial Of High Dose Interleukin 2 With TNF Receptor IGG ChimeraNational Center For Research Resources1996–1997
- Phase II Study Of Recombinant IL-6 Administered By ONE Hour InfusionsNational Center For Research Resources1996
- Phase I Dose Escalation Study Of Recombinant Human Interleukin 12National Center For Research Resources1996
- Multipart Phase I Clinical Trial Of High Dose IL 2 In Combination With IL 1National Center For Research Resources1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: